Transcriptional profiling of multiple sclerosis: Towards improved diagnosis and treatment

Expert Review of Molecular Diagnostics

Volumn 6, Issue 6, 2006, Pages 843-855

  Lindberg, Raija L P ^a,b   Kappos, Ludwig ^c  

^a Departments of Neurology and Research   (Switzerland)

^b Pharmazentrum   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Biomarker; Diagnosis; Gene expression; Interferon ; Microarray; Multiple sclerosis; Prognosis

Indexed keywords

BETA INTERFERON; BIOLOGICAL MARKER; GLATIRAMER; OLIGONUCLEOTIDE;

AUTOPSY; BRAIN BIOPSY; BRAIN TISSUE; DISEASE COURSE; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENE TARGETING; GENETIC TRANSCRIPTION; GENOME; HUMAN; MICROARRAY ANALYSIS; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TREATMENT RESPONSE;

ANIMALS; BRAIN; GENE EXPRESSION PROFILING; HUMANS; MULTIPLE SCLEROSIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TRANSCRIPTION, GENETIC;

EID: 33845437985     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.6.6.843     Document Type: Review

References (56)

1. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47, 707-717 (2000). •• Excellent article of the pathogenesis of MS.
2. Lassmann H, Bruck W, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol. Med. 7, 115-121 (2001). •• Relates the pathogenesis of multiple sclerosis (MS) to diagnosis and therapy.
3. McDonald WI, Compston A, Edan G et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 50, 121-127 (2001).
4. Polman CH, Reingold SC, Edan G et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann. Neurol. 58(6), 840-846 (2005). •• Important paper for diagnostic criteria of MS.
5. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N. Engl. J.Med. 343, 938-952 (2000).
6. Confavreux C, Vukusic S. Natural history of multiple sclerosis: implications for counselling and therapy. Curr. Opin. Neurol. 15(3), 257-266 (2002).
7. Zamvil SS, Steinman L. Diverse targets for intervention during inflammatory and neurodegenerative phases of multiple sclerosis. Neuron 38(5), 685-688 (2003).
8. Goodin DS, Frohman EM, Garmany GP et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58, 169-178 (2002).
9. Rovaris M, Filippi M. Interventions for the prevention of brain atrophy in multiple sclerosis: current status. CNS Drugs 17, 563-575 (2003).
10. Molyneux PD, Kappos L, Polman C et al. The effect of interferon β-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. Brain 123, 2256-2263 (2000).
11. Comi G, Filippi M, Barkhof F et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357, 1576-1582 (2001).
12. Jacobs LD, Beck R, Simon JH et al. Intramuscular interferon b-1a therapy initiated during a first demyelinating event in multiple sclerosis. N. Engl. J. Med. 343, 898-904 (2000).
13. Kappos L, Polman CH, Freedman MS et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology (In press) (2006).
14. Steinman L, Zamvil S. Transcriptional analysis of targets in multiple sclerosis. Nat. Rev. Immunol. 3, 483-492 (2003). •• Potential of microarray technique for identification of new targets for MS.
15. Whitney LW, Becker KG, Tresser NJ et al. Analysis of gene expression in multiple sclerosis lesions using cDNA microarrays. Ann. Neurol. 46, 425-428 (1999).
16. Whitney LW, Ludwin SK, McFarland HF, Biddison WE. Microarray analysis of gene expression in multiple sclerosis and EAE identifies 5-lipoxygenase as a component of inflammatory lesions. J. Immunol. 121, 40-48 (2001).
17. Chabas D, Baranzini SE, Mitchell D et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 294, 1731-1735 (2001).
18. Lock C, Hermans G, Pedotti R et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 8, 500-508 (2002).
19. Mycko MP, Papoian R, Boschert U, Raine CS, Selmaj KW. cDNA microarray analysis in multiple sclerosis lesions: detection of genes associated with disease activity. Brain 126, 1048-1057 (2003).
20. Tajouri L, Mellick AS, Ashton KJ et al. Quantitative and qualitative changes in gene expression patterns characterize the activity of plaques in multiple sclerosis. Mol. Brain Res. 119, 170-183 (2003).
21. Graumann U, Reynolds R, Steck AJ, Schaeren-Wiemers N. Molecular changes in normal appearing white matter in multiple sclerosis are characteristic of neuroprotective mechanisms against hypoxic insult. Brain Pathol. 13, 554-573 (2003).
22. Lindberg RLP, De Groot CJA, Certa U et al. Multiple sclerosis as a generalized CNS disease - comparative microarray analysis of normal appearing white matter (NAWM) and lesions in secondary progressive MS. J. Neuroimmunol. 152, 154-167 (2004).
23. Mycko MP, Papoian R, Boschert U, Raine CS, Selmaj KW. Microarray gene expression profiling of chronic active and inactive lesions in multiple sclerosis. Clin. Neurol. Neurosurg. 106, 223-229 (2004).
24. Dutta R, McDonough J, Yin X et al. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann. Neurol. 59, 478-489 (2006).
25. Tajouri L, Mellick AS, Tourtellotte A, Nagra RM, Griffiths LR. An examination of MS candidate genes identified as differentially regulated in multiple sclerosis plaque tissue, using absolute and comparative real-time Q-PCR analysis. Brain Res. Brain Res. Protoc. 15, 79-91 (2005).
26. Baranzini SE, Elfstrom C, Chang SY et al. Transcriptional analysis of multiple sclerosis brain lesions reveals a complex pattern of cytokine expression. J. Immunol. 165, 6576-6582 (2000).
27. Aitman TJ. DNA microarrays in medical practice. Br. Med. J. 323, 611-615 (2001). • Clinical view of the potential of microarrays.
28. Sinclair C, Mirakhur M, Kirk J, Farrell M, McQuaid S. Up-regulation of osteopontin and alphaBeta-crystallin in the normal-appearing white matter of multiple sclerosis: an immunohistochemical study utilizing tissue microarrays. Neuropathol. Appl. Neurobiol. 31(3), 292-303 (2005).
29. Blom T, Franzen A, Heinegard D, Holmdahl R. Comment on "The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease". Science 299, 1845 (2003).
30. Cwiklinska H, Mycko M, Luvsannorov O et al. Heat shock protein 70 associations with myelin basic protein and proteolipid protein in multiple sclerosis brains. Int. Immunol. 24, 1-9 (2003).
31. Birnbaum G, Kotilinek L. Heat shock or stress proteins and their role as autoantigens in multiple sclerosis. Ann. NY Acad. Sci. 835, 157-167 (1997).
32. Aquino DA, Capello E, Weisstein J et al. Multiple sclerosis: altered expression of 70-and 27-kDa heat shock proteins in lesions and myelin. J. Neuropathol. Exp. Neurol. 56, 664-672 (1997).
33. Ramanathan M, Weinstock-Guttman B, Nguyen LT et al. In vivo gene expression revealed by cDNA arrays: the pattern in relapsing-remitting multiple sclerosis patients compared with normal subjects. J. Neuroimmunol. 116, 213-219 (2001).
34. Wandinger KP, Sturzebecher CS, Bielekova B et al. Complex immunomodulatory effects of interferon-b in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Ann. Neurol. 50, 349-357 (2001).
35. Bomprezzi R, Ringner M, Kim S et al. Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease. Hum. Mol. Genet. 12, 2191-2199 (2003).
36. Sturzebecher S, Wandinger KP, Rosenwald A et al. Expression profiling identifies responder and non-responder phenotypes to interferon-b in multiple sclerosis. Brain 126, 1419-1429 (2003).
37. Koike F, Satoh J-I, Miyake S et al. Microarray analysis identifies interferon β-regulated genes in multiple sclerosis. J. Immunol. 139, 109-118 (2003).
38. Weinstock-Guttman B, Badgett D, Patrick K et al. Genomic effects of IFN-β in multiple sclerosis patients. J. Immunol. 171, 2694-2702 (2003).
39. Hong J, Zang YCQ, Hutton G, Rivera VM, Zhang JZ. Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis. J. Immunol. 152, 126-139 (2004).
40. Iglesias AH, Camelo S, Hwang D, Villanueva R, Stephanopoulos G, Dangond F. Microarray detection of E2F pathway activation and other targets in multiple sclerosis peripheral blood mononuclear cells. J. Neuroimmunol. 150, 163-177 (2004).
41. Achiron A, Gurevich M, Friedman N, Kaminski N, Mandel M. Blood transcriptional signatures of multiple sclerosis: unique gene expression of disease activity. Ann. Neurol. 55, 410-417 (2004).
42. Mandel M, Gurevich M, Pauzner R, Kaminski N, Achiron A. Autoimmunity gene expression portrait: specific signature that intersects or differentiates between multiple sclerosis and systemic lupus erythematosus. Clin. Exp. Immunol. 138, 164-170 (2004).
43. + cells from multiple sclerosis patients and is involved in T cell adhesion. Eur. J. Immunol. 34, 1217-1227 (2004).
44. Baranzini SE, Mousavi P, Rio J et al. Transcription-based prediction of response to IFNb using supervised computational methods. PLoS. Biol. 3, E2 (2005).
45. Satoh J, Nakanishi M, Koike F et al. Microarray analysis identifies an aberrant expression of apoptosis and DNA damage-regulatory genes in multiple sclerosis. Neurobiol. Dis. 18, 537-550 (2005).
46. Infante-Duarte C, Weber A, Kratzschmar J et al. Frequency of blood CX3CR1-positive natural killer cells correlates with disease activity in multiple sclerosis patients. FASEB J. 19, 1902-1904 (2005).
47. Satoh J, Nakanishi M, Koike F et al. T cell gene expression profiling identifies distinct subgroups of Japanese multiple sclerosis patients. J. Neuroimmunol. 174, 108-118 (2006).
48. Whitney AR, Diehn M, Popper SJ et al. Individuality and variation in gene expression patterns in human blood. Proc. Natl Acad. Sci. USA 100, 1896-901 (2003).
49. Radich JP, Mao M, Stepaniants S et al. Individual-specific variation of gene expression in peripheral blood leukocytes. Genomics 83(6), 980-988 (2004). • Important article of pitfalls of expression profiling in peripheral blood.
50. Salvetti M, Ristori G, Buttinelli C et al. The immune response to mycobacterial 70-kDa heat shock proteins frequently involves autoreactive T cells and is quantitatively disregulated in multiple sclerosis. J. Neuroimmunol. 65, 143-153 (1996).
51. Laroia G, Cuesta R, Brewer G, Schneider RJ. Control of mRNA decay by heat shock-ubiquitin-proteasome pathway. Science 284, 499-502 (1999).
52. Ben Dor L, Bruhn L, Friedman N, Nachman I, Schummer M, Yakhini Z. Tissue classification with gene expression profiles. J. Comput. Biol. 7, 559-583, (2000).
53. Liang Y, Tayo B, Cai X, Kelemen A. Differential and trajectory methods for time course gene expression data. Bioinformatics 21, 3009-3016 (2005).
54. Satoh J, Nanri Y, Tabunoki H, Yamamura T. Microarray analysis identifies a set of CXCR3 and CCR2 ligand chemokines as early IFNβ-responsive genes in peripheral blood lymphocytes in vitro: an implication for IFNβ-related adverse effects in multiple sclerosis. BMC Neurol. 6, 18 (2006).
55. Jayapal M, Melendez AJ. DNA microarray technology for target identification and validation. Clin. Exp. Pharmacol. Physiol. 33, 496-503 (2006). •• Excellent article of the current state of microarray technology in drug target identification.
56. Langmann T, Mauerer R, Schmitz G. Human ATP-binding cassette transporter taqman low-density array: analysis of macrophage differentiation and foam cell formation. Clin. Chem. 52, 310-313 (2006).